大血管急性缺血性卒中患者桥接治疗后出血转化相关因素的回顾性分析  

Retrospective Analysis of Related Factors of Bleeding Transformation in Patients with Acute Ischemic Stroke after Bridging Therapy

作　　者：张泓娇 杨玉超[1] 张晓琳[1] ZHANG Hongjiao;YANG Yuchao;ZHANG Xiaolin(Fushun Mining Bureau General Hospital of Liaoning Health Industry Group,Fushun 113008,Liaoning Province,China)

机构地区：[1]辽宁健康产业集团抚顺矿务局总医院,辽宁抚顺113008

出　　处：《中国实用乡村医生杂志》2022年第11期30-33,共4页Chinese Practical Journal of Rural Doctor

摘　　要：目的回顾性分析大血管急性缺血性卒中(acute ischemic stroke,AIS)患者桥接治疗后出血转化(hemorrhagic transformation,HT)的相关因素。方法回顾性收集2018年1月—2021年12月辽宁健康产业集团抚顺矿务局总医院收治的符合研究条件的大血管AIS患者184例,依据是否出现HT分为对照组(非HT组)132例和研究组(HT组)52例。对两组患者的临床资料进行综合分析,筛选桥接治疗后HT的相关因素。结果单因素和多因素logistic回归分析显示,年龄>70岁、糖尿病、美国国立卫生研究院卒中量表(NIHSS)评分>18分、大面积脑梗死、血小板计数<1.85×10^(11)/L、溶栓时间窗长、穿刺时间窗长是桥接治疗后HT的危险因素(P<0.05);而建立侧支循环是桥接治疗后HT的保护因素(P<0.05)。结论对于存在高危因素的AIS患者,桥接治疗后应警惕HT的出现。Objective To retrospectively analyze the related factors of haemorrhagic transformation(HT)in patients with acute ischemic stroke(AIS)after bridging therapy.Methods Retrospective collection of 184 patients with large vessel AIS admitted to Fushun Mining Bureau General Hospital of Liaoning Health Industry Group from January 2018 to December 2021,who met the study conditions,were divided into the control group(non HT group,n=132 cases)and the study group(HT group,n=52 cases)according to whether there was HT.The clinical data of the two groups were comprehensively analyzed to screen the relevant factors of HT after bridging therapy.Results Univariate and multivariate logistic regression analysis showed that age>70,diabetes mellitus,NIHSS score>18,massive cerebral infarction,platelet count<1.85×10^(11)/L,long thrombolytic time window and long puncture time window were the risk factors of HT after bridging treatment(P<0.05).The establishment of collateral circulation was the protective factor of HT after bridging therapy(P<0.05).Conclusion For AIS patients with high risk factors,HT should be vigilant after bridge therapy.

关 键 词：缺血性卒中 急性 桥接治疗 出血转化 危险因素 保护因素 

分 类 号：R651[医药卫生—外科学]